[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Haematology](https://durgical.com/en/haematology/) › [Blood and how to read it](https://durgical.com/en/haematology/areas/foundations/) › Why blood cancers start: driver mutations, clonal haematopoiesis and inherited risk

# Why blood cancers start: driver mutations, clonal haematopoiesis and inherited risk

- Foundations

Blood cancers start when a blood stem cell collects a few key mutations. Knowing which ones explains the disease and often picks the drug.

Updated Nov 15, 2026

## Key points

- Cancer = a clone with a few drivers; most mutations are passengers.
- Accelerator (kinases), maturation block (fusion genes), brakes (TP53), blocked death (BCL2).
- Clonal haematopoiesis: common with age, small yearly cancer risk, higher cardiovascular risk.
- Germline testing uses skin, not blood.
- Radiation, benzene, previous chemotherapy, EBV and [HTLV-1](https://durgical.com/en/microbiology/human-t-lymphotropic-virus-type-1/) are classic causes.

On this page

- The basics Key points
- What it is
- How to think about it
- What to know
- Driver jobs, examples and why they matter
- How it shows in the patient
- How to use it in practice
- Common traps
- Elsewhere in DurgiPedia

- Study Test yourself

- Connections Connections

## What it is

A haematological cancer is a clone: the descendants of one cell that has acquired changes in its DNA giving it an advantage. A few 'driver' changes cause the cancer; many others are passengers. Drivers fall into a small number of jobs: switching on growth signals, blocking maturation, changing how genes are read (epigenetic regulators), disturbing [RNA splicing](https://durgical.com/en/biochemistry/topics/rna-processing/), removing the guardians that stop damaged cells, and blocking cell death. Clones with a single driver are common in older healthy people (clonal haematopoiesis). Inherited variants, radiation, some chemicals and drugs, and certain infections raise the risk.

## How to think about it

A cell becomes a cancer the way a car becomes a runaway: one fault is rarely enough. Jam the accelerator (a growth signal stuck on, such as BCR::ABL1 or JAK2), stop the driver from ever learning to stop (a maturation block, such as PML::RARA), cut the brakes (TP53 lost) and disable the airbags that should end the trip (BCL2 overexpressed). The kind and number of faults decide whether you get a slow drift (chronic disease) or a crash ([acute leukaemia](https://durgical.com/en/conditions/acute-leukaemia/)).

## What to know

- Growth signals stuck on: BCR::ABL1 in CML, JAK2 V617F in [polycythaemia vera](https://durgical.com/en/conditions/polycythaemia-vera/) and other MPNs, FLT3 in AML; these kinases are targets for [kinase inhibitors](https://durgical.com/en/pharmacology/classes/kinase-inhibitors/).
- Maturation blocked: fusion genes of [transcription factors](https://durgical.com/en/biochemistry/topics/transcription/), such as PML::RARA in [acute promyelocytic leukaemia](https://durgical.com/en/general-pathology/acute-promyelocytic-leukaemia/), which differentiating drugs can overcome.
- Epigenetic and splicing genes (DNMT3A, TET2, ASXL1, [IDH1](https://durgical.com/en/biochemistry/enzymes/isocitrate-dehydrogenase/) /2, SF3B1) are typical of MDS, AML and clonal haematopoiesis.
- Death blocked or growth driven by translocations to immunoglobulin genes: BCL2 in [follicular lymphoma](https://durgical.com/en/general-pathology/follicular-lymphoma/), MYC in [Burkitt lymphoma](https://durgical.com/en/general-pathology/burkitt-lymphoma/), cyclin D1 in mantle cell lymphoma.
- Clonal haematopoiesis: a blood-cell mutation in a person with normal counts; it becomes common with age, carries a small yearly risk of blood cancer and is linked to cardiovascular disease.
- Precursor states exist across blood cancers: clonal haematopoiesis before MDS and AML, MGUS before myeloma, monoclonal B-cell lymphocytosis before CLL.
- Inherited risk: [Down syndrome](https://durgical.com/en/conditions/down-syndrome/) (leukaemias in childhood), [Fanconi anaemia](https://durgical.com/en/conditions/fanconi-anaemia/) (marrow failure and AML), Li-Fraumeni syndrome (TP53) and germline variants in genes such as RUNX1, GATA2 and DDX41.
- Environmental causes: [ionising radiation](https://durgical.com/en/biochemistry/topics/radioactivity-and-radiation-the-basics-for-medicine/), benzene, previous chemotherapy (therapy-related myeloid neoplasms), smoking; infections such as EBV, HTLV-1, HIV, hepatitis C and [Helicobacter pylori](https://durgical.com/en/microbiology/helicobacter-pylori/) drive some lymphomas.

## Driver jobs, examples and why they matter

| Driver job | Example change | Disease | Why it matters clinically |
| --- | --- | --- | --- |
| Growth signal stuck on | BCR::ABL1; JAK2 V617F; FLT3 | CML; MPNs; AML | Diagnostic test and target for kinase inhibitors |
| Maturation blocked | PML::RARA | Acute promyelocytic leukaemia | Emergency diagnosis; differentiating treatment |
| Gene reading altered (epigenetic, splicing) | DNMT3A, TET2, IDH1/2, SF3B1 | Clonal haematopoiesis, MDS, AML | Risk group; some are drug targets (IDH) |
| Guardian lost | TP53 deletion or mutation | AML, MDS, CLL, myeloma | Poor response to standard chemotherapy |
| Cell death blocked or growth forced | BCL2, MYC, cyclin D1 translocations | Follicular, Burkitt, mantle cell lymphoma | Diagnosis by [FISH](https://durgical.com/en/histology/immunohistochemistry-and-in-situ-hybridization/); BCL2 is a drug target |

## How it shows in the patient

- Genetic results at diagnosis often decide the risk group and whether a stem cell transplant is offered in first remission.
- A therapy-related myeloid neoplasm years after chemotherapy or [radiotherapy](https://durgical.com/en/nursing/radiation-therapy-skin-care-fatigue-and-safety-with-implants-and-radioactive-sou/) usually carries high-risk genetics.
- Children with Down syndrome have a higher risk of leukaemia, and newborns with Down syndrome can have a transient abnormal myelopoiesis that usually resolves on its own.
- HTLV-1, which causes adult T-cell leukaemia/lymphoma, is endemic in some communities of the Colombian Pacific; EBV is linked to Burkitt and [Hodgkin lymphoma](https://durgical.com/en/conditions/hodgkin-lymphoma/) and to lymphomas after transplant.

## How to use it in practice

- New acute leukaemia, MDS or myeloma: karyotype, FISH and a mutation panel at diagnosis, before treatment.
- Suspected MPN: JAK2 V617F first, then CALR and MPL if negative; suspected CML: BCR::ABL1 in the blood.
- Young patient, family history of blood cancers or marrow failure, or a mutation that may be inherited: germline testing on a non-blood tissue (skin fibroblasts), and before choosing a related donor.
- Clonal haematopoiesis found by chance: no treatment; follow the count and address cardiovascular risk factors.

## Common traps

- **Assuming a mutation found in blood or marrow is inherited, or acquired, without checking a non-blood tissue**: tumour cells contaminate blood samples.
- **Choosing a sibling donor without excluding the same inherited variant**: the donor's marrow can carry the risk.
- **Treating clonal haematopoiesis as a cancer**: most people with it never develop one.
- **Leaving previous chemotherapy or radiotherapy out of the history**: in a new AML or MDS, ask about both.

## Test yourself

Think of the answer, then tap the question to see it.

## Why is germline testing for an inherited blood cancer variant done on skin rather than blood?

Blood and marrow contain the cancer clone, whose acquired mutations would be mistaken for inherited ones; skin fibroblasts carry only the inherited DNA.

## What is clonal haematopoiesis and why does it matter?

A mutated blood-cell clone in a person with normal counts; it rises with age, carries a small risk of blood cancer and a higher risk of cardiovascular disease.

## Why do BCR::ABL1 and JAK2 V617F respond to targeted drugs?

Both make a [tyrosine](https://durgical.com/en/biochemistry/molecules/tyrosine/) kinase signal that is stuck on; kinase inhibitors block that signal, which the cancer cells depend on.

## Why must the history of a new AML include previous chemotherapy and radiotherapy?

Earlier cancer treatment can cause therapy-related myeloid neoplasms, which usually have high-risk genetics and a worse outlook.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/haematology/why-blood-cancers-start-driver-mutations-clonal-haematopoiesis-and-inherited-ris/)

## Elsewhere in DurgiPedia

- [Oncogenes: RAS, MYC, HER2, BCR-ABL and the table to know](https://durgical.com/en/general-pathology/oncogenes-ras-myc-her2-bcr-abl-and-the-table-to-know/)
- [Tumour suppressor genes: RB, TP53, APC, BRCA and the two-hit hypothesis](https://durgical.com/en/general-pathology/tumour-suppressor-genes-rb-tp53-apc-brca-and-the-two-hit-hypothesis/)
- [Chemical carcinogens: initiation, promotion and the table to know](https://durgical.com/en/general-pathology/chemical-carcinogens-initiation-promotion-and-the-table-to-know/)
- [Radiation and cancer: ultraviolet and ionizing](https://durgical.com/en/general-pathology/radiation-and-cancer-ultraviolet-and-ionizing/)
- [Oncogenic viruses and H. pylori: the table to know](https://durgical.com/en/general-pathology/oncogenic-viruses-and-h-pylori-the-table-to-know/)
- [Chronic myeloid leukaemia](https://durgical.com/en/general-pathology/chronic-myeloid-leukaemia/)

## Connections

## Related 5

- [Marrow aspirate and biopsy, flow cytometry and genetics: which test answers which question](https://durgical.com/en/haematology/marrow-aspirate-and-biopsy-flow-cytometry-and-genetics-which-test-answers-which/)
- [Acute leukaemias: AML, ALL and the emergency called APL](https://durgical.com/en/haematology/acute-leukaemias-aml-all-and-the-emergency-called-apl/)
- [Myeloproliferative neoplasms and myelodysplasia: too much or made badly](https://durgical.com/en/haematology/myeloproliferative-neoplasms-and-myelodysplasia-too-much-or-made-badly/)
- [CML on tyrosine kinase inhibitors: response milestones and resistance](https://durgical.com/en/haematology/cml-on-tyrosine-kinase-inhibitors-response-milestones-and-resistance/)
- [A paraprotein: MGUS, smouldering myeloma, myeloma or Waldenström?](https://durgical.com/en/haematology/a-paraprotein-mgus-smouldering-myeloma-myeloma-or-waldenstrom/)

## Related conditions 7

- [Acute leukaemia (AML and ALL)](https://durgical.com/en/conditions/acute-leukaemia/)
- [Chronic myeloid leukaemia](https://durgical.com/en/conditions/chronic-myeloid-leukaemia/)
- [Myelodysplastic syndromes](https://durgical.com/en/conditions/myelodysplastic-syndromes/)
- [Polycythaemia vera](https://durgical.com/en/conditions/polycythaemia-vera/)
- [Down syndrome (trisomy 21)](https://durgical.com/en/conditions/down-syndrome/)
- [Fanconi anaemia](https://durgical.com/en/conditions/fanconi-anaemia/)
- [Non-Hodgkin lymphoma](https://durgical.com/en/conditions/non-hodgkin-lymphoma/)

[← All of haematology](https://durgical.com/en/haematology/)

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: [What Is Cancer?](https://www.cancer.gov/about-cancer/understanding/what-is-cancer) (National Cancer Institute (NCI), 2026); [Li-Fraumeni syndrome: MedlinePlus Genetics](https://medlineplus.gov/genetics/condition/li-fraumeni-syndrome/) (MedlinePlus, US National Library of Medicine, 2026); [Risk Factors: Radiation - NCI](https://www.cancer.gov/about-cancer/causes-prevention/risk/radiation) (National Cancer Institute, 2026); [Chronic myeloid leukemia: MedlinePlus Genetics](https://medlineplus.gov/genetics/condition/chronic-myeloid-leukemia/) (MedlinePlus, US National Library of Medicine, 2026).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/haematology/why-blood-cancers-start-driver-mutations-clonal-haematopoiesis-and-inherited-ris/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/haematology/why-blood-cancers-start-driver-mutations-clonal-haematopoiesis-and-inherited-ris/
